Sequenom (Sequenom) Days Payable : 49.19 (As of Jun. 2016)

View and export this data going back to 2000. Start your Free Trial

What is Sequenom Days Payable?

Sequenom's average Accounts Payable for the three months ended in Jun. 2016 was $7.4 Mil. Sequenom's Cost of Goods Sold for the three months ended in Jun. 2016 was $13.8 Mil. Hence, Sequenom's Days Payable for the three months ended in Jun. 2016 was 49.19.

The historical rank and industry rank for Sequenom's Days Payable or its related term are showing as below:

SQNM's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 148.78
* Ranked among companies with meaningful Days Payable only.

Sequenom's Days Payable increased from Jun. 2015 (31.44) to Jun. 2016 (49.19). It may suggest that Sequenom delayed paying its suppliers.

Sequenom Days Payable Historical Data

The historical data trend for Sequenom's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sequenom Days Payable Chart

Sequenom Annual Data

Trend

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Days Payable

Get a 7-Day Free Trial

99.53

96.12

53.42

33.18

30.86

Sequenom Quarterly Data
	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16
Days Payable	Get a 7-Day Free Trial															31.44	37.78	33.28	33.43	49.19

Competitive Comparison of Sequenom's Days Payable

For the Biotechnology subindustry, Sequenom's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sequenom's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sequenom's Days Payable distribution charts can be found below:

* The bar in red indicates where Sequenom's Days Payable falls into.

Sequenom Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Sequenom's Days Payable for the fiscal year that ended in Dec. 2015 is calculated as

	Days Payable (A: Dec. 2015 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2014 )	+	Accounts Payable (A: Dec. 2015 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2015 )	*	Days in Period
=	( (6.089	+	5.234)	/	2 )	/	66.952	*	365
=	5.6615					/	66.952	*	365
=	30.86

Sequenom's Days Payable for the quarter that ended in Jun. 2016 is calculated as:

	Days Payable (Q: Jun. 2016 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Mar. 2016 )	+	Accounts Payable (Q: Jun. 2016 ))	/	count )	/	Cost of Goods Sold (Q: Jun. 2016 )	*	Days in Period
=	( (7.078	+	7.75)	/	2 )	/	13.754	*	365 / 4
=	7.414					/	13.754	*	365 / 4
=	49.19

Sequenom Days Payable Related Terms

Thank you for viewing the detailed overview of Sequenom's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Sequenom (Sequenom) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sequenom Inc (NAS:SQNM) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.sequenom.com

Sequenom Inc was incorporated in 1994 under the laws of the State of Delaware. It is a life science company providing revolutionary genomic and genetic analysis solutions for the molecular diagnostic and clinical research markets. It develop and commercialize molecular diagnostics testing services that target and serve molecular diagnostics markets, and also develop and commercialize research use genetic analysis products and services that target and serve discovery and clinical research markets. It offers its services and products in the United States and international emphasis in countries like European and Asia-Pacific regions. The Company operates in two operating segments; Sequenom Laboratories and Sequenom Bioscience. Sequenom Laboratories provides molecular based, laboratory developed tests, or LDTs, with a focus principally on prenatal diseases and conditions and ophthalmological diseases and conditions. Sequenom Bioscience provides technology and research tools for genetic analysis and applications in translational research, clinical research, pharmacogenomics, oncology, and agricultural genomics. The Company's competitors include; Ariosa Diagnostics, Inc., Beijing Genomics Institute, Cellscape Corp., Celula Inc., Ikonysis, Inc., Kellbenx, Inc., Laboratory Corporation of America Holdings, Inc., Natera, Perkin Elmer, Inc., Quest Laboratories, Verinata and others. Its patent portfolio, including in-licensed patent rights, includes approximately 638 issued or allowed patents in the United States and other industrial nations throughout the world. Its prenatal diagnostic patent portfolio includes exclusive rights to numerous in-licensed issued patents. The Company is subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of such materials and chemicals, as well as certain waste products.

Executives

Richard A Lerner	director	THE SCRIPPS RESEARCH INSTITUTE, 10550 N. TORREY PINES ROAD, LA JOLLA CA 92037
Kenneth F Buechler	director
Charles P Slacik	director	250 S. KRAEMER BLVD, BREA CA 92821
Jeffrey D Linton	officer: Sr VP, GC & Secretary	3525 PIEDMONT RD., NE, BUILDING 6, SUITE 700, ATLANTA GA 30305
Catherine J Mackey	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Carolyn Beaver	officer: SVP & CFO	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Benjamin R Miller	director	430 SOUTH SPRING STREET, BURLINGTON NC 27215
William Haas	director
Goldman Myla Lai	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Eberts F Samuel Iii	director, officer: Chairman, President & Sec	22 W FRONTAGE ROAD, NORTHFIELD IL 60093
Glenn A Eisenberg	director, officer: EVP and Treasurer	P O BOX 1017, CHARLOTTE NC 28201-1017
Van Der Vaart Sandra D	director	531 SOUTH SPRING STREET, BURLINGTON NC 27215
David Pendarvis	director	REDMED INC, 14040 DANLELSON ST, POWAY CA 92064
Camber Capital Management Lp	10 percent owner	101 HUNTINGTON AVENUE, SUITE 2101, BOSTON MA 02199
William J Welch	officer: President & CEO	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121